Molecular and Clinical Characteristics of Different Toxicity Rates in Anti-CD19 Chimeric Antigen Receptor T Cells: Real-World Experience

SIMPLE SUMMARY: Our real-world experience confirmed that commercial CART therapy can be administered with minimal toxicity. The early referral of patients with low tumor burdens is important as CAR T indications continue to expand. Furthermore, close monitoring and the early recognition of side effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Gavriilaki, E., Mallouri, D., Bousiou, Z., Demosthenous, C., Vardi, A., Dolgyras, P., Batsis, I., Stroggyli, E., Karvouni, P., Masmanidou, M., Gavriilaki, M., Bouinta, A., Bitsianis, S., Kapravelos, N., Bitzani, M., Vasileiadou, G., Yannaki, E., Sotiropoulos, D., Papagiannopoulos, S., Kazis, D., Kimiskidis, V., Anagnostopoulos, A., Sakellari, I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487155/
https://www.ncbi.nlm.nih.gov/pubmed/37686529
http://dx.doi.org/10.3390/cancers15174253

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487155/
https://www.ncbi.nlm.nih.gov/pubmed/37686529
http://dx.doi.org/10.3390/cancers15174253

Ejemplares similares